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48 Poster Session Ienhancement to determine the role of contact, the effect on prolif-
eration and apoptosis, as well as possible molecular mechanisms.
Methods: CD34-selected or non-selected UCB cells were co-cul-
tured with MSC under serum-free conditions. CD451 and
CD341 cells were detected b flow-cytometry. Progenitor function
was determined by colony forming unit assay. Non-viable and early
apoptotic cell detection was based on 7-Amino-ActinomycinD/An-
nexin-V staining. Cell cycle analysis was based on propidium iodide
staining. Results: CD341 selected as well as non-selected UCB
cells had 2 to 5 fold enhancement of growth when cultured on
MSCs compared to expansion in cytokines alone. Over 90% of
the proliferative activities were contributed by the CD34-selected
cells. Progenitor cells expanded rapidly only during the first 7
days of co-culture but declined afterwards. The enhancement on
UCB expansion was maximized when the MSC layer was in direct
contact with the UCB cells. UCB cells co-cultured with MSC re-
sulted in 2- to 4-fold lower apoptotic cell fraction, andUCB cell-cy-
cling activities were not affected. Conclusions: The main
mecahnism of enhancement of CBU cultures on MSC co-cultures
appears to be due to rescue of cells from apoptosis during the initial
few days of culture rather than due to a direct effect on augmenting
proliferation. The molecules involved in this interaction aree being
investigated in our laboratory.125
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Background: Autologous hematopoeitic stem cell transplanta-
tion (auto-HSCT) comprises the manipulation of bone marrow
and peripheral blood HSC by cryopreservation and posterior thaw-
ing. These manipulations can cause cell damage, especially in pa-
tients submitted to aggressive induction remission chemotherapy,
radiation and auto-HSCT conditioning. Study Design and
Methods: Thirty-two bone marrow samples (22 patients and 10
controls) were collected at pre-mobilization phase and 27 (20 pa-
tients and 7 controls) at post-mobilization, respectively. Fresh or
cryopreserved mononuclear cells were cultured for eleven months
and had their confluency capacity analyzed. Results: In regard to
confluency achievement, there was no difference between fresh
and cryopreserved samples from pre-mobilization phase. Apart
from this, cells from 6 of the 11 (54%) fresh samples collected
from patients at pre-mobilization phase achieved $70% conflu-
ency. Cells from all (5 of 5, 100%) fresh control samples collected
at this phase and from 4 of the 5 (80%) cryopreserved, achieved
$70% confluency. Cells from 5 of the 10 (50%) fresh samples col-
lected from patients during the post-mobilization and 4 of the 10
(40%) cryopreserved samples reached$70% confluency. Consider-
ing the control group from this phase, cells from half (1 of 2) of the
fresh samples and from 1 of the 5 cryopreserved samples, achieved
$70% confluency. Conclusion: Stroma establishment from nor-
mal hematopoietic progenitors post mobilization is reduced when
compared to samples obtained from patients with hematologic ma-
lignancies, most probably due to higher sensitivity of healthy pro-
genitor cells to cryopreservation and thawing-induced damage.126
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Background: mesenchymal stromal cells are immunomodoula-
trory and may have important role in engraftement and GVHD/
HVGD. we studied co-transplantation of ex vivo expanded MSCs
andHSC.Patients andMethods: In this study, we coadministered
culture-expanded MSCs with HLA-identical sibling-matched
HSCs in b-thalassemia patients. Between Nowember 2006 and
February 2007, 10 ß-thalassemia patients were enrolled. Patients re-
ceived Cyclophosphamide-based or Fludarabine –based condition-
ing regimens and short course methotrexate and cyclosporine as
GVHD prophylaxis. On day 0, patients were given MSCs intrave-
nously (1.0–2.24  106/kg) 4 hours before infusion of either bone
marrow or peripheral blood stem cells. Outcomes of transplantation
compared between these patients with 50 matched - historical con-
trols group which were transplanted with HSCs in last years.
Matching criteria were included: recipients’ gender, source of
stem cell (bone marrow or peripheral blood), thalassemia group (in-
termediate or major), class of ß-thalassemia major (I, II, III) . Re-
sults: Chills and fever was only notable toxicity in MSC group.
The median time to achieve WBC engraftment $0.5  109/L
was 12.5 days (range 10–20 days) forMSC group and 12 days (range
6–52 days) in matched-historical control group (p-value 5 0.67).
Themedian time to achieve platelet engraftment$20 109/Lwas
18 days (range 12–30 days) forMSC group and 22 days (range 10–81
days) for comparison group (p-value 5 0.02). Incidence of acute
GVHDwas 80% and 76% inMSC and historical-matched group re-
spectively (p-value 5 1). 3-month overall survival rate was 90% and
91.7% in MSC and matched control group respectively (p-value 5
0.29). 100-day disease free survival rate was 80% and 87.8% in
MSC group and matched historical control group respectively (p-
value 5 0.27). Conclusion: In this study we demonstrated that co-
transplantation of HLA-identical sibling MSCs with HSCs is seems
to be safe. we can’t find statistical significant difference in acute
GVHD incidence, severity, OS, DFS, Median time to WBC recov-
ery between MSC group and compartion group.most probably ex-
plantation is small number of patients in study group.median time
to plt recovery was shorter in MSC group (p-value 5 0.02).
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Objectives: Mesenchymal stem cells (MSC) suppress alloanti-
gen-induced proliferation, interferon-g (IFN-g) production and
cytolytic killing in vitro and infusion of third-party MSC appears
a promising therapy for acute GVHD. However, little is known
about the specificity of immunosuppression by MSC and in partic-
ular the effect on cell-mediated immunity to infectious pathogens.
We have studied the effect of MSC on virus-specific T-cell re-
sponses. Results: Peripheral blood mononuclear cells (PBMC)
from 6 normal donors were stimulated for with autologous lympho-
blastoid cell lines (LCL) (EBV), pp65 peptides (CMV), an adenovi-
ral vector Ad5f35 (Ad) or allogeneic PBMC (Allo), in the presence
or absence of third-party MSC (MSC/PBMC ratio 1:10). MSC sig-
nificantly suppressed proliferation in response to Allo (mean 61%
suppression, p 5 0.003), but had less effect on the response to
EBV (mean 42% suppression, p 5 0.016) and no suppression of
the response to CMV or Ad. MSC had no effect on expansion of
EBV and CMV pentamer-specific T-cells after stimulation with
their cognate antigen. ELISPOT assays demonstrated that MSC
significantly inhibited IFN-g production in response to Allo
(mean SFC/105 cells 1125 6 274 without MSC, 263 6 49 with
MSC) and to a smaller extent to EBV (3181 6 548 vs 2147 6
387), but not to CMV (2535 6 374 vs 2532 6 311). Established
EBV-specific cytotoxic T-cells (EBV-CTL) from 5 donors were
